Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of Mycobacterium ulcerans Disease

PLoS Neglected Tropical Diseases

Volumn 7, Issue 2, 2013, Pages

  Almeida, Deepak V ^a   Converse, Paul J ^a   Li, Si Yang ^a   Tyagi, Sandeep ^a   Nuermberger, Eric L ^a   Grosset, Jacques H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; BURULI ULCER; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; FOOT PAD; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STATISTICAL ANALYSIS; SWELLING; TREATMENT DURATION;

EID: 84874785123     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002085     Document Type: Article

References (27)

1. Asiedu K, Sherpbier R, Raviglione MC, editors. (2000) Buruli ulcer: Mycobacterium ulcerans infection. WHO/CDS/CPE/GBUI/2000.1. Geneva: WHO. 160 p.
2. Converse PJ, Nuermberger EL, Almeida DV, Grosset JH, (2011) Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol 6: 1185-1198.
3. World Health Organization (2008) Buruli ulcer progress report, 2004-2008. Wkly Epidemiol Rec 83: 145-154.
4. Walsh DS, Portaels F, Meyers WM, (2011) Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin 29: 1-8.
5. Chan-Tompkins NH, (1995) Toxic effects drug interactions of antimycobacterial therapy. Clin Dermatol 13: 223-233.
6. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, et al. (2006) Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 174: 94-101.
7. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, et al. (2007) Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4: e344.
8. Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V, (2007) Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 51: 3737-3739.
9. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011) Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis 5: e933.
10. World Health Organization (2004) Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). WHO/CDS/CPE/GBUI/10. Geneva: WHO. http://www.who.int/buruli/information/antibiotics/en/.
11. Ji B, Chauffour A, Aubry A, Robert J, Ibrahim M, Jarlier V, (2009) Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother 53: 2955-2959.
12. Grosset J, Ji B (1998) Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, editors. Mycobacteria: Chemotherapy. Chapman & Hall, New York. pp 51-97.
13. Pettit JHS, Marchette NJ, Rees RJW, (1966) Mycobacterium ulcerans infection. Clinical and bacteriological study of the first cases recognized in South East Asia. Br J Dermatol 78: 187-197.
14. George KM, Barker LP, Welty DM, Small PL, (1998) Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect Immun 66: 587-93.
15. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J, (2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46: 3193-3196.
16. Shepard CC, (1960) The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice. J Exp Med 112: 445-454.
17. Shepard CC, (1969) Further experience with the kinetic method for the study of drugs against Mycobacterium leprae in mice. Activities of DDS, DFD, ethionamide, capreomycin and PAM 1392. Int J Lepr Other Mycobact Dis 37: 389-397.
18. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 35: 1-39.
19. Andries K, Gevers T, Lounis N, (2010) Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother 54: 4540-4544.
20. Burman WJ, Gallicano K, Peloquin C, (2001) Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 40: 327-341.
21. Mitchison DA, (1998) Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 2: 612-615.
22. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agent Chemother 47: 2118-2124.
23. Jindani A, Doré CJ, Mitchison DA, (2003) Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167: 1348-1354.
24. WHO Expert Committee on Leprosy (2012). Eighth report. WHO Technical Report Series. Geneva: WHO. http://apps.who.int/iris/bitstream/10665/75151/1/WHO_TRS_968_eng.pdf.
25. World Health Organization (2012). WHO Drug Study Protocol for Buruli Ulcer- Comparison of SR8 and CR8. Registry File Number: T9-370-115.
26. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL, (2012) Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56: 4331-40.
27. Canetti G (1955). The tubercle bacillus in the pulmonary lesion of man. New York: Springer Publishing Company. 226 p.